Novabridge Biosciences (NBP) stock
NASDAQ
As of the Nov 13, 2026 close (U.S. Eastern)
- Market cap
- $100M
- Date not confirmed
- P/E
- -2.17x
- Latest fiscal year
- P/B
- 0.43x
- Latest reported equity
- P/S
- 25.00x
- Latest fiscal year
- ROE
- -19.9%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
- Market cap
- $100M
- Date not confirmed
- P/E
- -2.17x
- Latest fiscal year
- P/B
- 0.43x
- Latest reported equity
- P/S
- 25.00x
- Latest fiscal year
- ROE
- -19.9%
- Latest fiscal year
- Dividend yield
- Not available
- Latest fiscal-year dividends
The price date behind the multiples is not confirmed; they may differ from the current price.
Compares the share price with the company's earnings, net assets and sales. Check trading status and financial notes separately.
Price date for the multiples · not confirmed · Financial period · Latest fiscal year
Latest fiscal-year financials · Computed in-house by ChickenStock
P/E
-2.17x
Net loss — not comparable
P/B
0.43x
P/S
25.00x
Earnings and dividend metrics▾
Earnings
EPS
-$0.17
Earnings per share
BPS
$0.87
Book value per share
ROE
-19.9%
Return on equity
- EPS — what one share earned over the last four quarters. The company is currently loss-making, at $0.17 per share.
- BPS — net assets divided by the number of shares. Each share is backed by $0.87 of net assets.
- ROE — shareholder equity shrank by 19.9% over a year.
ⓘ What are these valuation metrics?▾
P/E = share price ÷ earnings per share (EPS)
P/B = share price ÷ book value per share (BPS)
P/S = share price ÷ sales per share
P/E shows how many times annual earnings per share the price is; not all earnings are paid to shareholders. P/B compares the price with net assets, and P/S with sales.
Higher or lower is not good or bad by itself. Typical levels differ by industry; read P/B alongside ROE and P/S alongside margins.
ChickenStock computes these from SEC financial filings: net income and revenue are summed over the latest four quarters, and equity is the latest reported balance.
A negative P/E means a net loss. Reference information only, not a recommendation to buy or sell.
Latest earnings
Recent results in a standard quarterly format were not found in SEC filings.
Some foreign companies file only annual or current reports, so quarterly figures may be missing.
See recent SEC filings →Insider transactions
Recent Form 4 filings grouped by person, date and transaction type.
- Woo Ian YingDirector · Oct 15, 2026Option exercise13,271 shares13,271 shares held after
- Dennis Phillip AndrewChief Medical Officer · Sep 18, 2026Open-market sale8,209 shares · $6KAvg. price $0.71173,427 shares held after
- Dennis Phillip AndrewChief Medical Officer · Sep 17, 2026Option exercise23,695 shares181,636 shares held after
- Cao Sean WuxiongChief Bus. Development Officer · Sep 9, 2026Open-market sale107,978 shares · $80KAvg. price $0.74266,467 shares held after
- Cao Sean WuxiongChief Bus. Development Officer · Sep 3, 2026Option exercise339,372 shares
Show 2 price lots
- 104,236 sharesValue not reported
- 235,136 sharesValue not reported
- Xu Cong ClaireEVP, Clinical Development · Aug 31, 2026Open-market sale3,282 shares · $3KAvg. price $0.79304,201 shares held after
- Xu Cong ClaireEVP, Clinical Development · Aug 30, 2026Option exercise9,382 shares307,483 shares held after
- Lenz Robert A.Director · Aug 22, 2026Option exercise17,218 shares17,218 shares held after
Only transactions reported on SEC Form 4 are shown. A sale may follow a pre-arranged 10b5-1 plan, and items such as option exercises or shares withheld for taxes are not open-market trades.
Recent SEC filings
40 filingsFilings submitted to the U.S. Securities and Exchange Commission (EDGAR). Dates are SEC filing dates (U.S. Eastern). Form and item names are the official SEC titles. The Earnings and Risk tags come directly from form types and item codes; they are not written by AI. Insider ownership reports (Forms 3, 4 and 5) are excluded.
Company overview
Expand ▾
Novabridge Biosciences (NBP) stock information
NASDAQ
Novabridge Biosciences (NBP) is listed on NASDAQ. Its market capitalization is about $100M. On trailing-twelve-month earnings the P/E ratio is -2.17, and the P/B ratio is 0.43. Return on equity is -19.9%. These figures are computed in-house from official filings and are reference information only.
Novabridge Biosciences — frequently asked questions
- What is the P/E ratio of Novabridge Biosciences (NBP)?
- On a trailing-twelve-month basis, NBP trades at a P/E ratio of -2.17. It is calculated as market capitalization divided by net income attributable to controlling interests, using official filings. Reference information only.
- What is the market capitalization of Novabridge Biosciences?
- NBP has a market capitalization of about $100M. The figure moves with the share price and is refreshed each trading day.
- Is this page investment advice?
- No. Every figure on this page is factual reference information compiled from public filings. It is not investment advice, not a price forecast and not a recommendation to buy or sell. Investment decisions rest with the user.
All metrics, scores, and content provided by ChickenStock are reference information derived from market data. They are not investment advice or a solicitation to trade. Investment decisions and their consequences rest with the user.